Search

Your search keyword '"Kullberg B"' showing total 531 results
Start Over Author "Kullberg B"

Refine your results

531 results on '"Kullberg B"'

3. Résultats par pathogènes en baseline et sensibilité dans l'essai de phase 3 ReSTORE de la rezafungine une fois par semaine vs caspofungine une fois par jour chez les patients atteints de candidémies et/ou de candidose invasive.

Author

Gangneux, J., primary, Thompson, G., additional, Soriano, A., additional, Cornely, O., additional, Kullberg, B., additional, Kollef, M., additional, Vazquez, J., additional, Das, A., additional, Locke, J., additional, and Karine, G., additional

Published
2023
Full Text
View/download PDF

5. P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis

Author

Soriano, A, primary, Thompson, G R, additional, Cornely, O A, additional, Kullberg, B J, additional, Kollef, M, additional, Vazquez, J, additional, Honore, P M, additional, Bassetti, M, additional, Pullman, J, additional, Dignani, C, additional, Das, A F, additional, Sandison, T, additional, and Pappas, P G, additional

Published
2023
Full Text
View/download PDF

7. Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An update including COVID-19 data

Author

Bassetti, M., Zuccaro, V., Asperges, E., Scudeller, L., Giacobbe, D. R., Akova, M., Alastruey-Izquierdo, A., Arikan-Akdagli, S., Azoulay, E., Blot, S., Cortegiani, A., Cornely, O. A., Grecchi, C., Lass-Florl, C., Koehler, P., Cuenca-Estrella, M., de Lange, D. W., De Rosa, F. G., De Waele, J. J., Dimopoulos, G., Garnacho-Montero, J., Hoenigl, M., Kanj, S. S., Lamoth, F., Maertens, J., Martin-Loeches, I., Munoz, P., Kullberg, B. J., Agvald-Ohman, C., Poulakou, G., Rebuffi, C., Rello, J., Sanguinetti, Maurizio, Taccone, F. S., Timsit, J. -F., Torres, A., Vazquez, J. A., Wauters, J., Calandra, T., Tejada, S., Karaiskos, I., Peghin, M., Vena, A., Mortensen, K. L., Lebihan, C., Mercier, T., Sanguinetti M. (ORCID:0000-0002-9780-7059), Bassetti, M., Zuccaro, V., Asperges, E., Scudeller, L., Giacobbe, D. R., Akova, M., Alastruey-Izquierdo, A., Arikan-Akdagli, S., Azoulay, E., Blot, S., Cortegiani, A., Cornely, O. A., Grecchi, C., Lass-Florl, C., Koehler, P., Cuenca-Estrella, M., de Lange, D. W., De Rosa, F. G., De Waele, J. J., Dimopoulos, G., Garnacho-Montero, J., Hoenigl, M., Kanj, S. S., Lamoth, F., Maertens, J., Martin-Loeches, I., Munoz, P., Kullberg, B. J., Agvald-Ohman, C., Poulakou, G., Rebuffi, C., Rello, J., Sanguinetti, Maurizio, Taccone, F. S., Timsit, J. -F., Torres, A., Vazquez, J. A., Wauters, J., Calandra, T., Tejada, S., Karaiskos, I., Peghin, M., Vena, A., Mortensen, K. L., Lebihan, C., Mercier, T., and Sanguinetti M. (ORCID:0000-0002-9780-7059)

Abstract

Not available

Published
2022

8. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures

Author

Cuenca-Estrella, M., Verweij, P. E, Arendrup, M. C, Arikan-Akdagli, S., Bille, J., Donnelly, J. P, Jensen, H. E, Lass-Flörl, C., Richardson, M. D, Akova, M., Bassetti, M., Calandra, T., Castagnola, E., Cornely, O. A, Garbino, J., Groll, A. H, Herbrecht, R., Hope, W. W, Kullberg, B. J, Lortholary, O., Meersseman, W., Petrikkos, G., Roilides, E., Viscoli, C., and Ullmann, A. J

Published
2012
Full Text
View/download PDF

11. Infectieziekten

Author

Kullberg, B. J., primary, van der Meer, J. W. M., additional, and Warris, A., additional

Published
2016
Full Text
View/download PDF

12. Borrelia burgdorferi is a poor inducer of interferon-gamma: amplification induced by interleukin-12

Author

van de Schoor, F R, Vrijmoeth, H D, Brouwer, M A E, Ter Hofstede, H J M, Lemmers, H L M, Dijkstra, H, Boahen, C K, Oosting, M, Kullberg, B J, Hovius, J W, van den Wijngaard, C C, van de Veerdonk, F L, Netea, M G, and Joosten, L A B

Abstract

Background Laboratory diagnosis of Lyme borreliosis (LB) is mainly based on serology, which has limitations, particularly in the early stages of the disease. In recent years there have been conflicting reports concerning a new diagnostic tool using the cytokine interferon-gamma (IFN-γ). Previous studies have generally found low concentrations of IFN-γ in early LB infection. The goal of this study is to investigate IFN-γ regulation during early LB and provide insights into the host response to B. burgdorferi. Methods We performed in vitro experiments with whole blood assays and peripheral blood mononuclear cells (PBMCs) of LB patients and healthy volunteers exposed to B. burgdorferi and evaluated the IFN-γ response using ELISA and related interindividual variation in IFN-γ production to the presence of single nucleotide polymorphisms. Results IFN-γ production of B. burgdorferi-exposed PBMCs and whole blood was amplified by the addition of IL-12 to the stimulation system. This effect was observed after 24 hours of B. burgdorferi stimulation in both healthy individuals and LB patients. The effect was highly variable between individuals, but was significantly higher in LB patients six weeks since the start of antibiotic treatment compared to healthy individuals. IL-12 p40 and IL-18 mRNA was upregulated upon exposure to B. burgdorferi, whereas IL-12 p35 and IFN-γ mRNA expression remained relatively unchanged. SNP Rs280520 in the downstream IL-12 pathway, Tyrosine Kinase 2, was associated with increased IFN-γ production. Conclusions This study shows that IL-12 evokes an IFN-γ response in B. burgdorferi exposed cells, and LB patients and healthy controls respond differently to this stimulation.

Published
2022

20. Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris

Author

Bruno, M. Kersten, S. Bain, J.M. Jaeger, M. Rosati, D. Kruppa, M.D. Lowman, D.W. Rice, P.J. Graves, B. Ma, Z. Jiao, Y.N. Chowdhary, A. Renieris, G. van de Veerdonk, F.L. Kullberg, B.-J. Giamarellos-Bourboulis, E.J. Hoischen, A. Gow, N.A.R. Brown, A.J.P. Meis, J.F. Williams, D.L. Netea, M.G.

Abstract

Candida auris is among the most important emerging fungal pathogens, yet mechanistic insights into its immune recognition and control are lacking. Here, we integrate transcriptional and functional immune-cell profiling to uncover innate defence mechanisms against C. auris. C. auris induces a specific transcriptome in human mononuclear cells, a stronger cytokine response compared with Candida albicans, but a lower macrophage lysis capacity. C. auris-induced innate immune activation is mediated through the recognition of C-type lectin receptors, mainly elicited by structurally unique C. auris mannoproteins. In in vivo experimental models of disseminated candidiasis, C. auris was less virulent than C. albicans. Collectively, these results demonstrate that C. auris is a strong inducer of innate host defence, and identify possible targets for adjuvant immunotherapy. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.

Published
2020

21. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, JP, Chen, SC, Kauffman, CA, Steinbach, WJ, Baddley, JW, Verweij, PE, Clancy, CJ, Wingard, JR, Lockhart, SR, Groll, AH, Sorrell, TC, Bassetti, M, Akan, H, Alexander, BD, Andes, D, Azoulay, E, Bialek, R, Bradsher, RW, Bretagne, S, Calandra, T, Caliendo, AM, Castagnola, E, Cruciani, M, Cuenca-Estrella, M, Decker, CF, Desai, SR, Fisher, B, Harrison, T, Heussel, CP, Jensen, HE, Kibbler, CC, Kontoyiannis, DP, Kullberg, B-J, Lagrou, K, Lamoth, F, Lehrnbecher, T, Loeffler, J, Lortholary, O, Maertens, J, Marchetti, O, Marr, KA, Masur, H, Meis, JF, Morrisey, CO, Nucci, M, Ostrosky-Zeichner, L, Pagano, L, Patterson, TF, Perfect, JR, Racil, Z, Roilides, E, Ruhnke, M, Prokop, CS, Shoham, S, Slavin, MA, Stevens, DA, Thompson, GR, Vazquez, JA, Viscoli, C, Walsh, TJ, Warris, A, Wheat, LJ, White, PL, Zaoutis, TE, Pappas, PG, Donnelly, JP, Chen, SC, Kauffman, CA, Steinbach, WJ, Baddley, JW, Verweij, PE, Clancy, CJ, Wingard, JR, Lockhart, SR, Groll, AH, Sorrell, TC, Bassetti, M, Akan, H, Alexander, BD, Andes, D, Azoulay, E, Bialek, R, Bradsher, RW, Bretagne, S, Calandra, T, Caliendo, AM, Castagnola, E, Cruciani, M, Cuenca-Estrella, M, Decker, CF, Desai, SR, Fisher, B, Harrison, T, Heussel, CP, Jensen, HE, Kibbler, CC, Kontoyiannis, DP, Kullberg, B-J, Lagrou, K, Lamoth, F, Lehrnbecher, T, Loeffler, J, Lortholary, O, Maertens, J, Marchetti, O, Marr, KA, Masur, H, Meis, JF, Morrisey, CO, Nucci, M, Ostrosky-Zeichner, L, Pagano, L, Patterson, TF, Perfect, JR, Racil, Z, Roilides, E, Ruhnke, M, Prokop, CS, Shoham, S, Slavin, MA, Stevens, DA, Thompson, GR, Vazquez, JA, Viscoli, C, Walsh, TJ, Warris, A, Wheat, LJ, White, PL, Zaoutis, TE, and Pappas, PG

Abstract

BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. METHODS: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. RESULTS: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. CONCLUSIONS: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

Published
2020

26. Acute disseminated encephalomyelitis associated with Borrelia burgdorferi

Author

Assen, S., Bosma, F., Staals, L. M. E., Kullberg, B. J., Melchers, W. J. G., Lammens, M., Kornips, F. H. M., Vos, P. E., and Fikkers, B. G.

Subjects
Encephalomyelitis -- Risk factors, Encephalomyelitis -- Research, Borrelia burgdorferi -- Complications and side effects, Borrelia burgdorferi -- Research, Health
Abstract

Byline: S. Assen (1,6), F. Bosma (3,6), L. M. E. Staals (2), B. J. Kullberg (1,6), W. J. G. Melchers (3,6), M. Lammens (4,5), F. H. M. Kornips (7), P. E. Vos (5), B. G. Fikkers (2) Author Affiliation: (1) University Medical Center St. Radboud, Dept. of General Internal Medicine, 9101, 6500, HB Nijmegen, The Netherlands (2) Dept. of Intensive Care Medicine, University Medical Center St. Radboud, Nijmegen, The Netherlands (3) Dept. of Clinical Microbiology, University Medical Center St. Radboud, Nijmegen, The Netherlands (4) Dept. of Pathology, University Medical Center St. Radboud, Nijmegen, The Netherlands (5) Dept. of Neurology, University Medical Center St. Radboud, Nijmegen, The Netherlands (6) Nijmegen University, Center for Infectious Diseases, Nijmegen, The Netherlands (7) Maxima Medical Center, Department of Neurology, Veldhoven, The Netherlands Article History: Registration Date: 01/01/2004 Received Date: 17/04/2003 Accepted Date: 16/01/2004

Published
2004

28. ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS

Author

Lortholary, O., Petrikkos, G., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., Cornely, O. A., Cuenca-Estrella, M., Donnelly, J. P., Garbino, J., Groll, A. H., Herbrecht, R., Hope, W. W., Jensen, H. E., Kullberg, B. J., Lass-Flörl, C., Meersseman, W., Richardson, M. D., Roilides, E., Verweij, P. E., Viscoli, C., and Ullmann, A. J.

Published
2012
Full Text
View/download PDF

29. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

Author

Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., Cuenca-Estrella, M., Donnelly, J. P., Garbino, J., Herbrecht, R., Jensen, H. E., Kullberg, B. J., Lass-Flörl, C., Lortholary, O., Meersseman, W., Petrikkos, G., Richardson, M. D., Verweij, P. E., Viscoli, C., and Ullmann, A. J.

Published
2012
Full Text
View/download PDF

30. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

Author

Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., Cornely, O. A., Donnelly, J. P., Garbino, J., Groll, A. H., Hope, W. W., Jensen, H. E., Kullberg, B. J., Lass-Flörl, C., Lortholary, O., Meersseman, W., Petrikkos, G., Richardson, M. D., Roilides, E., Verweij, P. E., and Cuenca-Estrella, M.

Published
2012
Full Text
View/download PDF

31. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

Author

Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Castagnola, E., Cuenca-Estrella, M., Donnelly, J. P., Groll, A. H., Herbrecht, R., Hope, W. W., Jensen, H. E., Lass-Flörl, C., Petrikkos, G., Richardson, M. D., Roilides, E., Verweij, P. E., Viscoli, C., and Ullmann, A. J.

Published
2012
Full Text
View/download PDF

32. ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases

Author

Ullmann, A. J., Cornely, O. A., Donnelly, J. P., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., Garbino, J., Groll, A. H., Herbrecht, R., Hope, W. W., Jensen, H. E., Kullberg, B. J., Lass-Flörl, C., Lortholary, O., Meersseman, W., Petrikkos, G., Richardson, M. D., Roilides, E., Verweij, P. E., Viscoli, C., and Cuenca-Estrella, M.

Published
2012
Full Text
View/download PDF

34. European expert opinion on the management of invasive candidiasis in adults

Author

Kullberg, B. J., Verweij, P. E., Akova, M., Arendrup, M. C., Bille, J., Calandra, T., Cuenca-Estrella, M., Herbrecht, R., Jacobs, F., Kalin, M., Kibbler, C. C., Lortholary, O., Martino, P., Meis, J. F., Muñoz, P., Odds, F. C., De Pauw, B. E., Rex, J. H., Roilides, E., Rogers, T. R., Ruhnke, M., Ullmann, A. J., Uzun, Ö., Vandewoude, K., Vincent, J.-L., and Donnelly, J. P.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results